Agenus Presents Phase 3 Trial Plans for BOT+BAL in MSS Colon Cancer

Bitget2026/11/05 15:25

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Agenus plans to start its Phase 3 ROBBIN trial of neoadjuvant botensilimab and balstilimab in MSS colon cancer by Q1 2027.
The FDA-aligned trial will enroll 850 patients, with event-free survival as its primary endpoint.
Across NEST and UNICORN, roughly 30% of 34 MSS patients achieved complete pathological responses; no recurrences occurred among all 52 combination-treated patients.
Interim event-free survival analysis is anticipated in the second half of 2029; final analysis is expected in the second half of 2030.
PIPE financing is expected to cover all ROBBIN costs and operating expenses through year-end 2031, assuming full warrant exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Agenus Presents Phase 3 Trial Plans for BOT+BAL in MSS Colon Cancer

You may also like

Crypto prices